Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Co. focuses on monoclonal antibodies, or mAbs, in the disease areas of immunology and oncology. A mAb is a type of protein that is produced by a single clone of cells or cell line and made to bind to a specific substance in the body. Co. has two product candidates: ONS-3010, a biosimilar to adalimumab (Humira®), and ONS-1045, a biosimilar to bevacizumab (Avastin®). We show 11 historical shares outstanding datapoints in our ONS shares outstanding history coverage, used to compute ONS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ONS market cap history over the course of time is important for investors
interested in comparing ONS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ONS versus a peer is one thing; comparing
ONS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ONS can fluctuate over the course of history.
With this page we aim to empower investors researching ONS by allowing them to research the ONS market cap history. |
Free ONS Email Alerts:
Video: The Importance of Market Cap
